Project Grant R01AR085007
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $4.13 million Project Grant to Icahn School of Medicine at Mount Sinai, effective September 1, 2025 through August 31, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research project, titled "Uncovering Novel Microbial Factors That Enhance Wound Repair," will investigate the role of specific...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded $267,423 to The Hospital for Special Surgery Fund, Inc. (HSS Foundation) on September 16, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This two-year-and-eleven-month project, concluding August 31, 2028, supports research to develop a novel biomarker for assessing immunosuppressive drug safety in patients with immune...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Trustees of The University of Pennsylvania a $100,331 Project Grant (CFDA 93.846: Arthritis, Musculoskeletal and Skin Diseases Research) effective May 5, 2026, through April 30, 2028. This research project investigates the roles of real-world shoulder biomechanics in rotator cuff tendinopathy rehabilitation. The research addresses the high non-response rate to...
- Federal Project Grant Award Summary The University of Texas at San Antonio received a $602,113 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective May 1, 2026 through April 30, 2031. The award supports research into browning of fatty infiltration in rotator cuff tears using novel nanotherapeutics. The research aims to address the challenge of...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $528,558 (awarded September 1, 2025, with completion by August 31, 2030) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research project investigates T-cell plasticity mechanisms underlying treatment resistance and paradoxical inflammatory side effects in atopic...
- Federal Project Grant Award Summary Icahn School of Medicine at Mount Sinai received a $250,396 Project Grant award dated September 5, 2025, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award supports research through August 31, 2027, focused on unraveling epigenetic and transcriptional control mechanisms in understudied skin types. The research will deliver...
- Federal Project Grant Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant totaling $3,056,688 to The Trustees of Columbia University in the City of New York (Health Sciences Division) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The three-year award, effective September 1, 2025, through August 31, 2028, funds fundamental research to elucidate the molecular mechanisms underlying skeletal muscle...
- Federal Project Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $243,192 Project Grant to Massachusetts General Hospital (MGH), effective November 1, 2025 through April 30, 2028, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This research project investigates the role of Wnt signaling in the mechanical maturation of tendon, with the primary objective of elucidating cellular and molecular...
- Federal Grant Award Summary The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded New Jersey Institute of Technology a $330,107 Project Grant effective September 1, 2025, through June 30, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award supports fundamental research investigating the role of stress anisotropy—directional stress differences in extracellular matrices—in fibroblast activation and its...
- The Defense Health Agency awarded a $749,991 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to the Icahn School of Medicine at Mount Sinai. The grant, titled "WNT-MODULATORY HYDROGEL PATCH FOR ROTATOR CUFF MUSCLE FATTY DEGENERATION", supports the development of an innovative hydrogel patch to address rotator cuff muscle fatty degeneration, a common condition affecting military personnel. The Icahn School of Medicine at Mount Sinai, a prominent...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $2,058,020 Project Grant to Icahn School of Medicine at Mount Sinai, effective June 1, 2026 through May 31, 2030, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). This award funds the development and validation of an engineered messenger RNA (mRNA) therapeutic designed to address rotator cuff muscle degeneration. The research will leverage lipid nanoparticles (LNPs) encapsulating WNT7A mRNA to promote muscle regeneration and prevent irreversible muscle atrophy and fatty infiltration following rotator cuff injury, addressing a critical therapeutic gap as current therapies fail to directly target muscle pathology despite failure rates exceeding 80% in surgical repair cases. The funded project encompasses three primary research aims: engineering and optimizing the W7A-LNP delivery platform while evaluating WNT7A expression kinetics and effects on muscle stem cell expansion and myofiber hypertrophy; determining therapeutic efficacy in preventing rotator cuff muscle degeneration; and assessing the platform's ability to reverse existing degeneration. Preliminary data demonstrate that W7A-LNP reduces fatty infiltration in both in vitro and in vivo models. The research conducted at the New York, NY location will generate preclinical data, animal model results, and mechanistic insights to support potential clinical translation of this regenerative medicine approach for treating rotator cuff injuries affecting over 250,000 individuals annually in the United States.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.1m | 5/13/26 |